Obesity Treatment to Improve Diabetes

• Status: Not yet recruiting
• Trial end date: 2024-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The obesity pandemic continues unabated, one can expect to see an increase in the prevalence of TID/T2D and associated CKD. As a result, death will rise, preceded by an increase in kidney failure, requiring dialysis and renal transplantation. Innovative medical treatment may help prevent CKD across our healthcare system. The guideline of the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) suggest that patients with obesity, TID/ T2D, and CKD needed either glucagon-like peptide 1 receptor analogs (GLP1-RA) or sodium-glucose cotransport-2 inhibits (SGLT2i). The clinical trials show the benefits of these medications in TID/T2D. This study will provide evidence of discrete metabolic pathways by the GLP1RA/or SGLT2i alone or in combination contributed to metabolic control.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dasman Diabetes Institute
• Treatments: Dapagliflozin; Glucagon; Glucagon-Like Peptide 1; Liraglutide

Criteria

inclusion criteria:

To be considered eligible to participate in this study, a patient must:

• Be aged between 21-65 years,

• Have a BMI ≥ 25 kg/m2,

• Have established diagnosis of Type 1 Diabetes

• Have established diagnosis of Chronic Kidney Disease(not applicable to patients undergoing bariatric surgery)

• Able to give informed consent

Exclusion criteria:

Participants will be excluded if:

•Have been treated with GLP-1 or SGLT2i within the last 3 months.